Publications by authors named "Paul I Thompson"
Background: Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC).
Methods: 49 patients with previously untreated mCRC were recruited.
Background And Purpose: Elective inguinal irradiation increases morbidity. We describe outcomes of moderate intensity chemoradiation treating anal canal and adjacent pelvic nodes only.
Material And Methods: Forty patients with T1-2, N0 anal carcinoma were enrolled between March 1999 and March 2003.
Article Synopsis
- DMXAA, an anticancer drug, caused temporary visual disturbances in patients, such as blurriness and color changes, particularly at higher doses.
- In a study with 21 patients, visual assessments showed that these disturbances peaked during treatment but generally resolved within 60 minutes.
- After further tests on 12 patients receiving DMXAA weekly, no lasting effects were found, suggesting that DMXAA's impact on vision is mainly acute and dose-dependent, without significant long-term damage.
Capecitabine, a new member of the fluoropyrimidine family, is an orally administered drug that delivers fluorouracil (5-FU) selectively to the tumour. Although the cardiotoxicity of 5-FU is well documented, there is little published data about cardiovascular adverse effects of Capecitabine. This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.
View Article and Find Full Text PDFBackground: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) appear to influence the growth of breast cancer cells in vitro, and epidemiological studies suggest higher serum IGF-I levels increase the risk of breast cancer. IGF-I and IGFBP-3 have therefore been measured in women with advanced breast cancer to determine if changes in serum levels predict the response to treatment by chemotherapy.
Methods: Serum IGF-I and IGFBP-3 levels were measured in 14 patients before and after 1 week of chemotherapy.